Spruce biosciences completes enrollment in cahmelia-204 study for adult classic congenital adrenal hyperplasia

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of enrollment in its cahmelia-204 clinical trial of tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (cah). “completing enrollment in our cahmelia-204 clinical trial marks a significant milest.
SPRB Ratings Summary
SPRB Quant Ranking